Highlights Newsletter 4
This newsletter presents you the following key sessions:
2. MYLUNG consortium: prospective evaluation of molecular testing practices in patients with newly
diagnosed non-small cell lung cancer in a real-world setting
3. Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC
4. Pembrolizumab plus chemotherapy holds promise for recurrent EGFR-mutant non-small cell lung cancer
5. Current status of lung cancer screening in Europe